The FDA approved Sanofi-Aventis' chemotherapy drug Jevtana for use in combination with prednisone in patients with advanced prostate cancer. The approval was based on studies that demonstrated a median overall survival of 15.1 months for men who received the combination, compared with 12.7 months for those who received mitoxantrone plus prednisone.

Related Summaries